Early Metastasis in Soft Tissue Sarcoma: Clinicopathologic Predictors and the Limits of Current Risk Stratification [0.03%]
Dorian Yarih Garcia-Ortega,Miguel Angel Clara Altamirano,Ana Paulina Melendez-Fernandez et al.
Dorian Yarih Garcia-Ortega et al.
Soft tissue sarcomas (STS) of the extremities and trunk are biologically heterogeneous, and distant metastasis remains the leading cause of disease-related mortality. A subset of patients develops metastases very early (≤12 months after di...
Intratumoral Heamorrhage Induced by Atezolizumab plus Bevacizumab Combination Therapy in Patients with Hepatocellular Carcinoma [0.03%]
Takashi Takeuchi,Hajime Yokota,Jun Koizumi et al.
Takashi Takeuchi et al.
Introduction The purpose of this study was to investigate the incidence, risk factors, and prognostic significance of intratumoral hemorrhage (ITH) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (...
Association of hypoglycemic agents with the risk of platinum-based chemotherapy-induced peripheral neuropathy in patients with type 2 diabetes mellitus [0.03%]
降糖药与铂类化疗诱发的外周神经病变的相关性分析
Takeshi Horii,Kenji Onda,Airi Yutasaka et al.
Takeshi Horii et al.
Introduction In patients with cancer who also have type 2 diabetes (T2D), platinum-based chemotherapy can worsen the neuropathy owing to its neurotoxicity. Glucose-lowering agents may mitigate chemotherapy-induced peripheral neuropathy by i...
Serum microRNA-122 predicts early progressive disease in unresectable hepatocellular carcinoma with atezolizumab plus bevacizumab therapy [0.03%]
血清微小核糖核酸-122可预测不可切除肝细胞癌阿特朱单抗联合贝伐珠单抗治疗早期进展性疾病
Shigeki Yamamoto,Norio Akuta,Tetsuya Hosaka et al.
Shigeki Yamamoto et al.
Introduction Atezolizumab plus bevacizumab is a standard first-line therapy for unresectable HCC; however, a proportion of patients develop early progressive disease (PD). Reliable pretreatment predictive biomarkers remain an unmet need. Th...
Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic Pathways [0.03%]
缺氧诱导的微小核糖核酸通过调节致癌通路赋予膀胱癌细胞生存优势
Takaya Ohno,Yuki Nakajima,Yuki Yoshikawa et al.
Takaya Ohno et al.
Introduction: Bladder cancer (BC) is influenced by hypoxic conditions, which promote tumor progression and resistance to therapy. MicroRNAs (miRNAs) play key roles in regulating gene expression under hypoxia. ...
Impact of Tyrosine Kinase Inhibitors on Estimated Glomerular Filtration Rate in Chronic Myeloid Leukemia Patients [0.03%]
酪氨酸激酶抑制剂对慢性髓性白血病患者肾小球滤过率的影响分析
Awni Alshurafa,Maria Benkhadra,Nabeel Mohammad Qasem et al.
Awni Alshurafa et al.
Introduction: Tyrosine kinase inhibitors (TKIs) are the cornerstone of therapy for chronic myeloid leukemia (CML). Although nephrotoxicity has been reported, existing evidence remains inconsistent, with limited data from ...
Transforming Acute Myeloid Leukemia Care Through Precision Medicine: Integrating Genomic Profiling, Measurable Residual Disease, and Targeted Therapies [0.03%]
精准医疗转化急性髓系白血病治疗：整合基因组分析、可测量残余疾病和靶向治疗
Rafal Al-Shibly,Maria Benkhadra,Mohamed A Yassin
Rafal Al-Shibly
Acute myeloid leukemia (AML) is a biologically heterogeneous and clinically aggressive hematologic malignancy, with outcomes that remain poor for many older adults and patients with adverse-risk disease. Advances in cytogenetics and next-ge...
Can splenic characteristics predict rectal cancer chemotherapy toxicity and treatment outcomes in rectal cancer patients? [0.03%]
脾脏特征能否预测直肠癌患者化疗毒性和治疗效果？
Lara Wirth,Alex Besson,Paige Hudson et al.
Lara Wirth et al.
Introduction: Rectal cancer requires multidisciplinary management, including chemotherapy treatment, for successful clinical outcomes. Splenic characteristics on CT imaging has been proposed to reflect immune function. Th...
Nivolumab versus Best Supportive Care after failure of Chemotherapy in Non-Small Cell Lung Cancer Patients with ECOG 3 or 4: A Propensity Matched Analysis [0.03%]
与最好支持治疗相比，尼伏单抗用于ECOG评分为3-4分的非小细胞肺癌患者二线及后线治疗：倾向匹配分析
Pawan Kumar Singh,Geetika Arya,Vineela Surapaneni et al.
Pawan Kumar Singh et al.
Introduction: Non small cell lung cancer (NSCLC) patients with poor Eastern Cooperative Oncology Group Performance Status (ECOG PS >2) represent a challenging subset of patients. Best supportive care (BSC) has been the st...
Association between antibiotic exposure and the risk of checkpoint inhibitor pneumonitis in lung cancer patients [0.03%]
抗生素暴露与肺癌患者免疫检查点抑制剂肺炎风险之间的关联
Deli Tan,Xiaohui Jia,Enyong Zhang et al.
Deli Tan et al.
Introduction: Checkpoint inhibitor pneumonitis (CIP) is a potentially fatal immune-related adverse event in patients receiving immune checkpoint inhibitors (ICIs). Antibiotics (ATBs) usage has risen among such patients, y...